Pharsight

1. Kinevac patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US6803046	November, 2018	Terminated-Denied	Bracco Diagnostics Inc.	Maia Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6803046	BRACCO	Sincalide formulations	Aug, 2022 (1 year, 1 month ago)

Drugs and Companies using SINCALIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
0.005MG/VIAL	INJECTABLE;INJECTION	Prescription

KINEVAC family patents

2. Lumason patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335502	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)
US10232061	BRACCO	Freeze-dried formulation for gas-filled microvesicles	Jul, 2038 (14 years from now)
US11723869	BRACCO	Freeze-dried product and gas-filled microvesicles suspension	May, 2039 (15 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population (NPP)	Nov 13, 2022

Drugs and Companies using SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES ingredient

Market Authorisation Date: 15 October, 2014

Treatment: Use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border; Use in ultrasonog...

Dosage: FOR SUSPENSION;INTRAVENOUS